Psilocybin

• The Center of Excellence for Psilocybin Research and Treatment is the first leading global site for the development of psychedelic therapeutics in the U.S.
• In his role as senior researcher, Dr. Johnson will join Sheppard Pratt in their efforts to integrate biological psychiatry with psychotherapy.
• Sheppard Pratt's Center of Excellence for Psilocybin Research and Treatment brings together evidence-based innovation and the development of psychedelic therapeutics on a large scale.
• To learn more about Sheppard Pratt's Institute for Advanced Diagnostics and Therapeutics and Center of Excellence for Psilocybin Research and Treatment, visit www.sheppardpratt.org/the-institute-for-advanced-diagnostics-and-therape... .

• Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company on its progress and achievements in 2023.
• Philip Young CEO commented, “2023 was a remarkable year that witnessed the company make important advancements in clinical development of our proprietary pharmaceutical products and the acquisition and commercial launch of Altemia, our novel medical formulation for Sickle Cell Disease.”
  Confirmed the improved pharmacokinetics of L-130 delivered as a shelf-stable capsule over its inactive prodrug, psilocybin
  “2023 was truly a transformative year for Lobe Sciences.
• The company plans to build on this momentum in 2024 and I look forward to updating our investors throughout 2024.”
  Management will be meeting with prospective investors and corporate partners during the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 8-11.
• To schedule a meeting please contact [email protected]

• Tel Aviv, Israel / Vancouver, Canada, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, reflects on the successful collaboration with SciSparc Ltd. (Nasdaq: SPRC) ("SciSparc") in 2023.
• Early in 2023, Clearmind filed six provisional patent applications with the United States Patent and Trademark Office for unique combinations of future psychedelic-based compounds.
• The patent applications were filed as part of Clearmind’s ongoing collaboration with SciSparc, a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.
• As part of the collaboration agreement between Clearmind and SciSparc, originally announced on March 8,2022, any assets generated from the collaboration shall be jointly owned by Clearmind and SciSparc .

• I don’t know whether he thought that it might reduce pain or improve performance, but the idea of taking drugs before “going into battle” goes back to the beginning of recorded history.
• Indeed, we find frequent mentions of mead drinking by the warriors in Edinburgh in the seventh-century epic poem The Goddodin.
• These ancient warriors probably used alcohol to reduce anxiety and blunt the horrors they would face on the battlefield.

• Pervitin (methamphetamine) was given almost freely to all arms of the German war machine.
• The frontline Nazis called them Panzerschokolade (tank chocolate), due to the feelings of incredible strength and invincibility that the pills gave them.

Behavioural effects

The types of drugs taken by warriors can be lumped into three broad categories: depressants, hallucinogens and stimulants. Alcohol is a depressant that calms the nerves by reducing brain activity. Psychedelic mushrooms such as Amanita muscaria contain a variety of psychoactive substances. Hyoscyamus niger also has a variety of active compounds that cause hallucinations and, importantly, aggressive and combative behaviour.

• The word “groggy” meaning dazed and unsteady came from British navy sailors exhibiting this behaviour after their daily ration of rum and water (grog).
• The stimulants, but especially methamphetamine, would also lead to significant weight loss even after only a few days of use.
• Long-term use, as we saw with the Nazis, would probably lead to emaciated soldiers.

Smart drugs

• We have seen that soldiers take drugs before battles to calm nerves, deal with the horrors, reduce pain, tolerate lack of food and sleep and improve alertness.
• The stimulants include drugs such as amphetamine salt mixtures, methylphenidate and modafinil, while nootropics include piracetam, caffeine, cobalamin (vitamin B12), guarana, pyridoxine (vitamin B6) and vinpocetine.
• The integration of humans, technology and machines is thought to be the future of warfare and drugs that facilitate this are undoubtedly being researched by the military.

Post-traumatic stress disorder

• There is a long history of soldiers taking alcohol and other drugs to deal with the horrors of what they have seen, or the disappointment of life after leaving the army.
• These veterans are taking MDMA and psilocybin on doctors’ orders as part of their treatment for PTSD.
• Ketamine is useful for treating depression and LSD is also being tested for various psychiatric disorders.

Colin Davidson has previously received funding from the US National Institute on Drug Abuse (NIDA). He is a consultant with the Defence Science and Technology Laboratory (UK).